Abatacept in Patients With Birdshot HLA A29 Uveitis
Status:
Active, not recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of Abatacept as an immunosuppressive treatment in Birdshot
uveitis. The primary objective is to test the efficacy to suppress inflammation in active
Birdshot uveitis patients, using quantitative and qualitative measurements of visual
function.